Open AccessCost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer
Author(s) -
Thomas E. Delea,
Carol Hawkes,
Mayur M. Amonkar,
Konstantinos Lykopoulos,
Stephen Johnston
Publication year - 2013
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000357316
Subject(s) - medicine , lapatinib , letrozole , breast cancer , oncology , anastrozole , aromatase inhibitor , metastatic breast cancer , gynecology , trastuzumab , cancer , aromatase
In the EGF30008 and TAnDEM (TrAstuzumab in Dual HER2 ER-positive Metastatic breast cancer) trials, anti-HER2 therapy plus an aromatase inhibitor (lapatinib + letrozole (LAP + LET) and trastuzumb + anastrozole (TZ + ANA), respectively) improved time to progression versus aromatase inhibitor monotherapy (LET and ANA, respectively) in post-menopausal women with previously untreated hormone receptor-positive (HR+) and HER2-positive (HER2+) metastatic breast cancer.